688189 南新制药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-4.369-31.865-0.830-5.823-10.832
总资产报酬率 ROA (%)-3.491-24.264-0.592-3.859-7.678
投入资产回报率 ROIC (%)-3.629-25.479-0.618-4.094-8.237

边际利润分析
销售毛利率 (%)40.88154.59184.47585.78887.125
营业利润率 (%)-71.067-147.393-1.296-10.512-28.852
息税前利润/营业总收入 (%)-72.719-148.165-0.576-9.810-28.734
净利润/营业总收入 (%)-70.864-150.891-1.499-13.968-24.539

收益指标分析
经营活动净收益/利润总额(%)72.30516.838-1,042.214-52.66046.545
价值变动净收益/利润总额(%)0.6260.000163.1597.610-1.551
营业外收支净额/利润总额(%)0.0370.148-2.1340.7390.105

偿债能力分析
流动比率 (X)2.5822.2902.9712.3082.391
速动比率 (X)2.3442.1102.9002.2662.300
资产负债率 (%)22.16828.15125.23033.67634.582
带息债务/全部投入资本 (%)14.14018.78420.31829.32128.971
股东权益/带息债务 (%)604.656430.395390.453239.254243.183
股东权益/负债合计 (%)377.297272.160300.481199.680189.065
利息保障倍数 (X)44.731267.428-0.831-12.573-194.419

营运能力分析
应收账款周转天数 (天)397.870489.690312.189339.743297.907
存货周转天数 (天)287.512137.81092.393160.282215.745